Related Experiment Video

Updated: Aug 16, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma

Maria G Fencer1,2, Catherine H Davis1,3, Jieqi Liu3

  • 1Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ, USA.

Journal of Investigative Medicine High Impact Case Reports
|December 21, 2022
PubMed

Insights

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare liver cancer. The IMbrave regimen (atezolizumab and bevacizumab) showed disease control in an SHCC patient, expanding treatment options for this variant.

Area of Science:

  • Hepatobiliary cancers
  • Oncology
  • Translational medicine

Background:

  • Sarcomatoid hepatocellular carcinoma (SHCC) is a rare, aggressive variant of liver cancer.
  • Limited effective treatment options exist for SHCC.
  • The IMbrave trial established atezolizumab and bevacizumab (A+B) for unresectable hepatocellular carcinoma, but excluded SHCC patients.

Observation:

  • This report details a case of SHCC.
  • The patient was treated with the IMbrave regimen (atezolizumab and bevacizumab).

Findings:

  • Disease control was achieved in the patient with SHCC receiving A+B.
  • This suggests potential efficacy of the IMbrave regimen in SHCC.

Implications:

  • The IMbrave regimen may offer a viable treatment strategy for patients with sarcomatoid hepatocellular carcinoma.
  • Further investigation into A+B for SHCC is warranted.
  • This case expands the potential therapeutic landscape for rare liver cancer variants.
Keywords:
atezolizumabbevacizumabhepatocellular carcinomasarcomatoid

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

550
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
624
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K